Syn-Ake
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic tripeptide mimicking waglerin-1 from Temple Viper venom, used topically to relax facial muscles and soften expression lines as a Botox alternative. Evidence remains limited, with laboratory findings and small industry-affiliated human studies. The main risk is poor skin penetration that may keep it from reaching muscle, plus inconsistent quality. It is a cosmetic ingredient, not an approved drug, sold in skincare products and as unregulated products online.
Read Full recordStudied uses & evidence
Studied uses(5)
Reduction of expression wrinkles and crow's feet
SpeculativeA 2026 controlled split-face pilot included five Syn-Ake participants; larger replication is needed.
Non-invasive muscle relaxation (topical Botox alternative)
SpeculativeReceptor inhibition has laboratory support. Human topical studies exist, but do not directly establish facial-muscle relaxation.
Antioxidant activity and ROS scavenging
SpeculativeBased on a single in vitro chemical assay, not cellular or human testing.
Evidence limits
- Evidence Level
- Moderate
The clinical evidence base for Syn-Ake is limited to manufacturer-sponsored efficacy data and supportive mechanistic research. The primary efficacy claim — up to 52% wrinkle reduction after 28 days — comes from Pentapharm's in-house in vivo study using 4% Syn-Ake cream, which measured skin surface parameters objectively (profilometry) but was not published in a peer-reviewed journal or independently replicated. The underlying mechanism (nAChR antagonism causing muscle relaxation) is well-supported by independent academic research on waglerin-1 peptides (Molles et al. 1999, McArdle et al. 2002). A 2024 study (Bang et al., PMID 39063099) independently confirmed Syn-Ake's nAChR inhibitory activity but primarily as a comparison control for a novel peptide. The 2024 review by Nguyen et al. in Cosmetics noted only six clinical validations total for Botox-like peptides (including Syn-Ake, Argireline, and SNAP-8). Major evidence gaps include: (1) no independent RCTs, (2) no long-term efficacy or safety data, (3) no head-to-head comparison with Botox or other neuromuscular peptides in peer-reviewed trials, and (4) the well-documented challenge of poor peptide permeability through the stratum corneum, which may limit in vivo efficacy compared to in vitro results.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Limited independent clinical validation
HighPoor skin penetration may limit efficacy
ModerateProduct quality variability
ModerateSkin irritation and allergic reaction
LowPregnancy and lactation safety unknown
LowAcute dermal toxicity at high concentrations
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.